Depression is among the most widespread mental health disorders worldwide, typically characterized by persistent feelings of sadness, a lack of interest in daily activities and dysregulated sleep and/or eating habits. There are now a wide range of pharmacological treatments for depression, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants and atypical antidepressants.
In recent years, some research groups have been exploring the potential of alternative treatments for depression that rely on psychedelic compounds, such as psilocybin. Psilocybin is a compound naturally found in more than 100 species of mushrooms, which can influence the mood and perceptions of those who ingest it.
Researchers at Imperial College London’s Center for Psychedelic Research recently carried out a study aimed at better understanding the effects of psilocybin treatment on the processing of music and the experience of emotions, comparing them to those of escitalopram, a widely used SSRI.